October 11, 2024

Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Size 2022-2030

According to Precedence Research, the global enzyme-linked immunosorbent assay (ELISA) testing market size is forecasted to reach US$ 4.02 billion by 2030 by growing at a lucrative CAGR of 6.4% between 2022 and 2030.

The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2022 to 2030. The report offers exclusive insights to help companies make informed decisions to sustain growth through the assessment period.

Crucial factors accountable for market growth are:

  • Growing incidence of infectious disorders such as hepatitis, dengue, and AIDS
  • Increasing prevalence of neurological disorders
  • Growing geriatric population
  • High research and development expenditure of major players
  • Growing per capita healthcare spending
  • Growing incidence of non-communicable diseases
  • Emergence of cost-effective technologies

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1260

Market Scope:

Report HighlightsDetails
Market SizeUSD 4.02 Billion by 2030
Growth RateCAGR of 6.4% From 2022 to 2030
Base Year2020
Forecast Period2022 to 2030
Segments CoveredTest, Application, Region
Key Considerations for Market Forecast:
  • Impact of lockdowns, supply chain disruptions, demand destruction, and change in customer behavior
  • Optimistic, probable, and pessimistic scenarios for all markets as the impact of pandemic unfolds
  • Pre- as well as post-COVID-19 market estimates
  • Quarterly impact analysis and updates on market estimates

North America is Estimated to be the Largest Market for Enzyme-Linked Immunosorbent Assay (ELISA) Testing

North America represents developed regional markets for enzyme-linked immunosorbent assay (ELISA) testing and is expected to see the rapid growth in the years to come. The U.S. is by far the leading enzyme-linked immunosorbent assay (ELISA) testing market by country in North America. The U.S. market is expected to grow at the highest CAGR during the forecast period. This growth is mainly due to the well-developed healthcare infrastructure and increases in research and development on enzyme-linked immunosorbent assay (ELISA) testing. Moreover, the disposable income and reimbursement of life threatening diseases are very high in this region which promotes the growth of enzyme-linked immunosorbent assay (ELISA) testing market.

Some of the prominent players in the global enzyme-linked immunosorbent assay (ELISA) testing market are listed as below:

  • Thermo Fisher Scientific, Inc.
  • American Laboratory Products Company (ALPCO)
  • Bio-Rad Laboratories, Inc.
  • BD
  • BioMérieux SA
  • Ortho Clinical Diagnostics
  • R&D Systems, Inc.
  • ZEUS Scientific, Inc.

In order to well recognize the present status of enzyme-linked immunosorbent assay (ELISA), and policies implemented by the foremost nations, Precedence Research projected the future progress of the enzyme-linked immunosorbent assay (ELISA) testing market. This research report bids quantitative and qualitative insights on enzyme-linked immunosorbent assay (ELISA) testing market and valuation of market size and progress trend for probable market segments.

Key Market Developments:

On November, 2019, ALPCO announced the official launch of its STELLUX Chemi Glucagon ELISA. The new chemiluminescence ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples.

Major Market Segments Covered:

By Test Type

  • Sandwich ELISA
  • Indirect ELISA
  • Multiple and Portable ELISA
  • Competitive ELISA
  • Others

By Application

  • Immunology
  • Inflammation
  • Infectious diseases
  • Cancer
  • Protein quantification
  • Other Applications

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, By Test Type

7.1. Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, by Test Type, 2022-2030

7.1.1. Sandwich ELISA

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Indirect ELISA

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Multiple and Portable ELISA

7.1.3.1. Market Revenue and Forecast (2017-2030)

7.1.4. Competitive ELISA

7.1.4.1. Market Revenue and Forecast (2017-2030)

7.1.5. Others

7.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, By Application

8.1. Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, by Application, 2022-2030

8.1.1. Immunology

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Inflammation

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Infectious diseases

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Cancer

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Protein quantification

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Other Applications

8.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, Regional Estimates and Trend Forecast

9.1. North America

9.1.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.2. Market Revenue and Forecast, by Application (2017-2030)

9.1.3. U.S.

9.1.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.1.4. Rest of North America

9.1.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.4.2. Market Revenue and Forecast, by Application (2017-2030)

9.2. Europe

9.2.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.2. Market Revenue and Forecast, by Application (2017-2030)

9.2.3. UK

9.2.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.2.4. Germany

9.2.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.4.2. Market Revenue and Forecast, by Application (2017-2030)

9.2.5. France

9.2.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

9.2.6. Rest of Europe

9.2.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

9.3. APAC

9.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.3.3. India

9.3.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.3.4. China

9.3.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.4.2. Market Revenue and Forecast, by Application (2017-2030)

9.3.5. Japan

9.3.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

9.3.6. Rest of APAC

9.3.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

9.4. MEA

9.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.2. Market Revenue and Forecast, by Application (2017-2030)

9.4.3. GCC

9.4.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.4.4. North Africa

9.4.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.4.2. Market Revenue and Forecast, by Application (2017-2030)

9.4.5. South Africa

9.4.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

9.4.6. Rest of MEA

9.4.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

9.5. Latin America

9.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.2. Market Revenue and Forecast, by Application (2017-2030)

9.5.3. Brazil

9.5.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.5.4. Rest of LATAM

9.5.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.4.2. Market Revenue and Forecast, by Application (2017-2030)

Chapter 10. Company Profiles

10.1. Thermo Fisher Scientific, Inc.

10.1.1. Company Overview

10.1.2. Product Offerings

10.1.3. Financial Performance

10.1.4. Recent Initiatives

10.2. American Laboratory Products Company (ALPCO)

10.2.1. Company Overview

10.2.2. Product Offerings

10.2.3. Financial Performance

10.2.4. Recent Initiatives

10.3. Bio-Rad Laboratories, Inc.

10.3.1. Company Overview

10.3.2. Product Offerings

10.3.3. Financial Performance

10.3.4. Recent Initiatives

10.4. BD

10.4.1. Company Overview

10.4.2. Product Offerings

10.4.3. Financial Performance

10.4.4. Recent Initiatives

10.5. BioMérieux SA

10.5.1. Company Overview

10.5.2. Product Offerings

10.5.3. Financial Performance

10.5.4. Recent Initiatives

10.6. Ortho Clinical Diagnostics

10.6.1. Company Overview

10.6.2. Product Offerings

10.6.3. Financial Performance

10.6.4. Recent Initiatives

10.7. R&D Systems, Inc.

10.7.1. Company Overview

10.7.2. Product Offerings

10.7.3. Financial Performance

10.7.4. Recent Initiatives

10.8. ZEUS Scientific, Inc.

10.8.1. Company Overview

10.8.2. Product Offerings

10.8.3. Financial Performance

10.8.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research

11.2. Secondary Research

11.3. Assumptions

Chapter 12. Appendix

12.1. About Us

12.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1260

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

View all posts by Precedence Research →